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A B S T R A C T T I T L E
Methylene blue (MB), a potential neuroprotective agent, is efficient in various neurodegenerative disease
models. Beneficial effects of MB have been attributed to improvements in mitochondrial functions. Sub-
strate-level phosphorylation (SLP) results in the production of ATP independent from the ATP synthase
(ATP-ase). In energetically compromised mitochondria, ATP produced by SLP can prevent the reversal of the
adenine nucleotide translocase and thus the hydrolysis of glycolytic ATP. The aim of the present study was
to investigate the effect of MB on mitochondrial SLP catalysed by succinyl-CoA ligase. Measurements were
carried out on isolated guinea pig cortical mitochondria respiring on α-ketoglutarate, glutamate, malate or suc-
cinate. The mitochondrial functions and parameters like ATP synthesis, oxygen consumption, membrane po-
tential, and NAD(P)H level were followed online, in parallel with the redox state of MB. SLP-mediated ATP
synthesis was measured in the presence of inhibitors for ATP-ase and adenylate kinase. In the presence of the
ATP-ase inhibitor oligomycin MB stimulated respiration with all of the respiratory substrates. However, the
rate of ATP synthesis increased only with substrates α-ketoglutarate and glutamate (forming succinyl–CoA).
MB efficiently stimulated SLP and restored the membrane potential in mitochondria also with the combined
inhibition of Complex I and ATP synthase. ATP formed by SLP alleviated the energetic insufficiency gener-
ated by the lack of oxidative phosphorylation. Thus, the MB-mediated stimulation of SLP might be important
in maintaining the energetic competence of mitochondria and in preventing the mitochondrial hydrolysis of
glycolytic ATP. The mitochondrial effects of MB are explained by the ability to accept electrons from reduc-
ing equivalents and transfer them to cytochrome c bypassing the respiratory Complexes I and III.
© 2016 Published by Elsevier Ltd.
1. Introduction
Methylene blue (MB) (for structure, see: Supplemental Data, Fig.
1) was identified as an antimalarial drug in 1891 (Guttman and
Ehrlich, 1891). In the last century, MB has been used for the treat-
ment of methemoglobinaemia (Mansouri and Lurie, 1993), carbon
monoxide and cyanide poisoning (Draize, 1933). It displayed benefi
Abbreviations: AK, adenylate kinase; ANT, adenine nucleotide translocase;
α-KG, alpha-ketoglutarate; α-KGDHc, alpha-ketoglutarate dehydrogenase com-
plex; AP5, P1,P5-di(adenosine-5′) pentaphosphate; BSA, bovine serum albumin;
CAT, carboxyatractilozide; Δψm, mitochondrial membrane potential; FCCP, car-
bonylcyanide-p-triflouromethoxy-phenylhydrazone; MDH, malate dehydroge-
nase; MB, methylene blue; OXPHOS, oxidative phosphorylation; SLP, sub-
strate-level phosphorylation; TCA cycle, tricarboxylic acid cycle
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cial effects in neurodegenerative disease models (Eckert et al., 2012;
Paban et al., 2014; Sontag et al., 2012; Zhang et al., 2006) and stroke
(Di et al., 2015). In Alzheimer's disease models MB augmented the
activity of Complex IV and stimulated the synthesis of heme (Atamna
et al., 2008).
The U.S. Food and Drug Administration (FDA) approved MB for
the emergency treatment of methemoglobinaemia (FDA Reference
ID: 3914270). MB provides an alternative mechanism for electron
transport by transferring electrons from NADH (Wen et al., 2011) and
FADH2 (Dixon, 1971) to cytochrome c (Atamna et al., 2008; McCord
and Fridovich, 1970) or molecular oxygen (Tretter et al., 2014). The
aromatic ring of MB provides high lipophilicity and consequently
good membrane permeability while the positive charge on MB secures
mitochondrial membrane potential (Δψm)-dependent accumulation in
the mitochondrial matrix (Gabrielli et al., 2004). As we have previ-
ously reported (Tretter et al., 2014), MB stimulates ATP synthesis,
rescues Δψm and increases Ca
2+ uptake in mitochondria with impaired
Complexes I and III.
http://dx.doi.org/10.1016/j.neuropharm.2017.05.009
0028-3908/© 2016 Published by Elsevier Ltd.
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In mitochondria, ATP can be produced via three mechanisms: i)
oxidative phosphorylation (OXPHOS), ii) SLP in the tricarboxylic
acid (TCA) cycle (catalyzed by succinyl-CoA ligase), and iii) the
adenylate kinase (AK) reaction (2 ADP ↔ ATP + AMP) (Bruns and
Regina, 1977; Nobumoto et al., 1998; Panayiotou et al., 2014). Mi-
tochondrial SLP is attributed to succinyl–CoA ligase, an enzyme of
the TCA cycle having two isoforms: an ATP-forming isoform (suc-
cinyl-CoA + ADP + Pi ↔ succinate + CoA-SH + ATP (EC: 6.2.1.5))
and a GTP-forming isoform (succinyl-CoA + GDP + Pi ↔ succi-
nate + CoA-SH + GTP (EC: 6.2.1.4)); both reactions are reversible
(Johnson et al., 1998). In rodent brain the ATP-forming isoform is
dominating (Lambeth et al., 2004; Ostergaard, 2008). SLP is consid-
ered to be an alternative mechanism for ATP synthesis inside the mito-
chondrion (Heldt and Schwalbach, 1967); it is practically independent
of the respiratory chain and the mitochondrial proton motive force.
Under physiological conditions SLP has an essential role in ATP pro-
duction during thermogenesis in brown-adipose tissue (Rafael et al.,
1974; Smith et al., 1966). Furthermore, SLP has a significant role
when OXPHOS is impaired (Chinopoulos, 2011b). Recently a new
and important role has also been attributed to matrix SLP. Mito-
chondria have been known to both synthesize and hydrolyze ATP
(Nicholls and Ferguson, 2013). The ATP hydrolytic activity of mito-
chondria is typically associated with the hydrolysis of glycolytic ATP
and the complete depletion of cellular ATP. In order to hydrolyze gly-
colytic ATP both the ATP synthase and adenine nucleotide translo-
case (ANT) have to work in their reverse modes. However, the rever-
sals of ATP synthase and ANT have been shown to occur nonsimul-
taneously because the reversal potentials of the two functions are dis-
similar (Chinopoulos, 2011b). ATP production via matrix SLP may
prevent the reversal of ANT and thus could inhibit the mitochondr-
ial utilisation of cytosolic ATP (Chinopoulos, 2011a). Metabolic inter-
mediates inside the mitochondrion can be classified as promoters and
non-promoters of the SLP (Kiss et al., 2013). To selectively measure
SLP activity both OXPHOS and AK-catalyzed ATP production have
to be minimized.
The aim of this study was to examine the effects of MB on ma-
trix SLP and mitochondrial bioenergetics in the presence of the ATP
synthase inhibitor oligomycin and the adenylate kinase inhibitor AP5
(see structure: Supplemental Data, Fig. 2) in isolated, intact brain
mitochondria. The concentrations of MB applied in this study
(300 nM–2 μM) corresponded to the blood levels of MB detected after
i.v. administration (Peter et al., 2000; Schirmer et al., 2011). Isolated
guinea pig brain mitochondria were supported with various respira-
tory substrates including α-ketoglutarate (α-KG), glutamate, malate,
or succinate. MB enhanced the rate of mitochondrial SLP in the pres-
ence of glutamate or α-KG, but did not stimulate the SLP with succi-
nate or malate. In the presence of the respiratory Complex I inhibitor
rotenone MB was still able to stimulate the SLP and could restore the
dissipated Δψm. The potentially neuroprotective drug MB could have
beneficial effects in OXPHOS-inhibited mitochondria.
2. Materials and methods
2.1. Chemicals
All laboratory chemicals except for ADP were purchased from
Sigma (St. Louis, MO, USA). ADP was purchased from Merck
(Darmstadt, Germany).
2.2. Preparation of brain mitochondria
Mitochondria were isolated from the brain cortex of albino male
guinea pigs using a Percoll gradient as previously described
(Rosenthal et al., 1987; Tretter and Adam-Vizi, 2007). Animal experi-
ments were performed in accordance with the guidance of the National
Institute of Health (USA) for the care and use of laboratory animals.
Brain was homogenised in ice cold buffer “A” (in mM: 225 mannitol,
75 sucrose, 5 HEPES, 1 EGTA, pH 7.4) and centrifuged for 3 min at
1300 g. Subsequently, the supernatant was centrifuged for 10 min at
20,000 g and the resultant pellet was resuspended in 15% Percoll and
layered on a discontinuous gradient (40 and 23%) of Percoll. This gra-
dient was then centrifuged for 8 min at 30,700 g using no brake at the
end. After resuspending the lower fraction in buffer “A”, the solution
was centrifuged at 16,600 g for 10 min, the resultant pellet was resus-
pended in buffer “A” and subsequently centrifuged again at 6300 g
for 10 min. After the supernatant was discharged, the pellet was resus-
pended in buffer “B”, which contained no EGTA (in mM: 225 man-
nitol, 75 sucrose, 5 HEPES, pH 7.4). Protein concentration was deter-
mined by the modified biuret method (Bradford, 1976). Unless oth-
erwise indicated, 0.1 mg/ml mitochondrial protein concentration was
used throughout the experiments.
2.3. Measurement of mitochondrial respiration
Oxygen consumption was measured by high-resolution respirom-
etry using an Oxygraph-2k instrument (OROBOROS Instruments,
Innsbruck, Austria). Standardised two-point calibrations of the polaro-
graphic oxygen sensor were applied (Pesta and Gnaiger, 2012). Mea-
surements were performed in an assay medium containing (in mM):
0.1 EGTA, 125 KCl, 20 HEPES, 2 K2HPO4, 1 MgCl2, and 0.025%
BSA (fatty acid-free) at pH 7.0. In all experiments, 200 μM AP5 was
used to inhibit AK isoforms. Data were digitally recorded using the
DatLab4 software (OROBOROS Instruments, Innsbruck, Austria).
2.4. Measurement of ATP production
To measure ATP production, a coupled enzyme assay applying
hexokinase and glucose-6-phosphate dehydrogenase was used
(Williamson and Corkey, 1979). The assay medium described above
was supplemented with 3 mM NADP+, 1.5 U hexokinase, 0.5 U glu-
cose-6-phosphate dehydrogenase, 5 mM glucose, and 200 μM AP5
(P1,P5-Di(adenosine-5′) pentaphosphate; an inhibitor of adenylate ki-
nase) in 2 ml total volume (Melnick et al., 1979). Throughout the mea-
surements, 0.05 mg/ml mitochondria and 2 mM ADP were used. In
the presence of mitochondria and the applied respiratory substrate(s)
ADP was phosphorylated to ATP. ATP left mitochondria via ANT.
Hexokinase in the medium phosphorylated glucose to glucose-6-phos-
phate using ATP. Then, glucose-6-phosphate was oxidized to 6-phos-
phogluconate by glucose-6-phospate dehydrogenase with the con-
comitant reduction of NADP+ to NADPH. NADPH formation was de-
tected as proportional to ATP released from the mitochondria. Ab-
sorbance of NADPH (ɛ = 6220 M−1cm−1) was recorded at 340 nm,
37 °C using a JASCO V-650 spectrophotometer (ABL&E-JASCO,
Tokyo, Japan). Measurements were calibrated using ATP standards.
To detect mitochondrial SLP, the following protocol was used: ADP
was first added to the mitochondria and subsequently, OXPHOS was
initiated by adding a respiratory substrate. Then, ATP synthase was
inhibited by oligomycin. Afterwards, MB was added. At the end of
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each experiment, ANT was blocked by the specific inhibitor carboxy-
atractylozide (CAT).
2.5. Measurement of mitochondrial membrane potential (Δψm)
The Δψm was detected using safranin O, a positively charged dye,
which undergoes an optical shift upon membrane potential distribu-
tion between the medium and the mitochondrial matrix (Akerman and
Wikstrom, 1976; Figueira et al., 2012). Safranin (2 μM) fluorescence
was measured with a Hitachi F-4500 spectrofluorimeter (Hitachi High
Technologies, Maidenhead, UK) at 495 and 585 nm excitation and
emission wavelengths at 37 °C, respectively. The assay medium was
the same as that for mitochondrial respiration. 0.1 mg/ml mitochondr-
ial protein concentration was used in the experiments.
2.6. Measurement of MB absorbance
Oxidised MB's absorbance was detected at 660 nm using a JASCO
V-650 spectrophotometer. 0.1 mg/ml mitochondrial protein concen-
tration was used throughout the experiments. Measurements were per-
formed in an assay medium containing (in mM): 0.1 EGTA, 125 KCl,
20 HEPES, 2 K2HPO4, 1 MgCl2 and 0.025% BSA (fatty acid-free) at
pH 7.0. MB (2 μM) was added at the beginning of each experiment.
2.7. Statistics
Data are presented as the means ± S.E.M. Significant differences
were evaluated with the one-way ANOVA procedure followed by the
Holm-Sidak's post-hoc test for multiple comparisons, or for data not
following normal distribution ANOVA on ranks Kruskar Wallis test
was applied. Values of p < 0.05 were considered to be significant.
3. Results
3.1. The contribution of adenylate kinase activity to mitochondrial
ATP production
In preliminary experiments, the addition of ADP to isolated mi-
tochondria in an ATP assay test resulted in a consistent, elongated
NAD(P)H H+ production in the absence of respiratory substrates. This
OXPHOS and SLP-independent ATP production could be attributed
to the presence of AKs (Barkulis and Lehninger, 1951; Panayiotou et
al., 2014). This high ATP synthetic activity could add a significant
“background” to the ATP measurements. To eliminate this activity, an
inhibitor of AKs, AP5 was used (Melnick et al., 1979). After titrat-
ing the AK-dependent ATP production with AP5, 200 μM AP5 was
the most effective concentration to inhibit mitochondrial AK activ-
ity without impairing mitochondrial respiration. In non-energised mi-
tochondria addition of 200 μM AP5 resulted a 83% decrease of the
rate of ATP production during the first 3 min (Fig. 1.) The residual
ATP production (22–23 nmol/min/mg protein) was also AP5 sensi-
tive, but the higher AP5 concentrations were toxic for mitochondria
(not shown). Carboxyatractilozide (CAT) an inhibitor of the ATP/
ADP exchange transporter (adenine nucleotide translocase; ANT) re-
sulted in a small decrease in ATP production both in the presence or
absence of AP5 indicating that most of the AK activity is localized
on the outer surface of the inner mitochondrial membrane (Fig. 1).
Off-target effects of AP5 were also detected, but those have not influ-
enced the validity of the results. These off-target effects are described
in the Supplementary material.
Fig. 1. The rate of ATP production as a function of time in the presence or absence of
200 μM AP5 in mitochondria devoid of respiratory substrates. Mitochondria (0.1 mg/
ml) were incubated in the standard medium as described under Materials and methods.
ADP (2 mM) was given as indicated. Numbers measured as the rate of ATP synthesis
are in nmol/min/mg protein mean ± SEM (n > 4). Trace a shows the rate of ATP syn-
thesis in the absence of AP5; trace b the rate of ATP synthesis in the presence of AP5.
3.2. The effect of MB on the rate of ATP synthesis (substrate level
phosphorylation) in oxidative phosphorylation-inhibited
mitochondria
In a previous study by us (Tretter et al., 2014) in Complex I or
complex III-compromised mitochondria MB, applied at 1 or 2 μM
concentrations significantly stimulated the OXPHOS-mediated ATP
generation; in the present study, 300 nM, 1 μM or 2 μM MB was ap-
plied. The contribution of SLP to gross ATP production was calcu-
lated by subtracting the ADP-evoked ATP production measured in
the absence of the respiratory substrate from the ATP production de-
tected in the presence of ADP, respiratory substrate and oligomycin.
Oligomycin, an inhibitor of the mitochondrial ATP synthase (also
known as F0F1ATP-ase) blocks OXPHOS, hence in its presence ATP
synthesis can be attributed exclusively to the AK activity plus SLP.
In α-KG-supported mitochondria, the basal SLP (SLP in the pres-
ence of oligomycin, but in the absence of MB) was found to be
(47 ± 3)-(23 ± 1) = 24 ± 2 nmol/min/mg protein (Fig. 2A and B). MB
stimulated the mitochondrial ATP synthesis with α-KG as respira-
tory substrate in a dose-dependent manner (Fig. 2B). The rate of ATP
production in the presence of oligomycin, ADP and α-KG was in-
creased by 26% after 300 nM MB was given (from 47 ± 3 nmol/min/
mg protein to 59 ± 4 nmol/min/mg protein), by 72% with 1 μM MB
(from 47 ± 3 nmol/min/mg protein to 81 ± 4 nmol/min/mg protein)
and by 104% with 2 μM MB (from 47 ± 3 nmol/min/mg protein to
96 ± 4 nmol/min/mg protein) (Fig. 2B). Addition of the ANT inhibitor
CAT lowered the rate of ATP production nearly to the level of control
(i.e. when only ADP and oligomycin were added) indicating that “ex-
cess” ATP is produced within the mitochondria and that ANT activity
was necessary to detect SLP-mediated ATP production.
Glutamate-energised mitochondria exhibited moderate levels of
basal SLP (31 ± 4)-(23 ± 1) = 8 ± 2 nmol/min/mg protein. MB (1 μM)
elevated the rate of ATP synthesis from 31 ± 4 to 54 ± 6 nmol/min/mg
protein (Fig. 2D).
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Fig. 2. The effect of MB on the rate of ATP synthesis in α-ketoglutarate (A,B), succinate (C), in glutamate (D) and malate (D) supported brain mitochondria. AP5 (200 μM) was added
to each sample. Mitochondria (0.05 mg/ml) were incubated in the standard medium as described under Materials and methods. ADP (2 mM), oligomycin (2 μM), MB (300 nM, 1 μM,
2 μM) and carboxyatractilozide (CAT; 2 μM) were given as indicated. Original traces are shown in (A) with numbers calculated as the rate of ATP synthesis in nmol/min/mg protein
in these particular experiments. The results are expressed as rate of ATP synthesis in nmol/min/mg protein mean ± SEM (n > 4) and written on the bars; *p < 0.05; ***p < 0.001. The
values n in the figures refer to the number of repetitions in each group.
In succinate-energised mitochondria, no basal SLP was detected
and the addition of MB did not enhance the rate of ATP generation
in the presence of oligomycin. In the absence of MB the rate of ATP
synthesis was found to be 19 ± 6 nmol/min/mg protein. In the pres-
ence of 300 nM MB, 21 ± 5 nmol/min/mg protein; with 1 μM MB,
19 ± 4 nmol/min/mg protein and with 2 μM MB, 24 ± 4 nmol/min/mg
protein rate of ATP production was detected after oligomycin was
given (Fig. 2C). These results indicate that succinate does not support
SLP in the TCA cycle.
Similarly to succinate, in malate-supported mitochondria a basal
level of SLP was not detectable. Moreover, MB (1 μM) did not in-
crease the rate of ATP production in OXPHOS-inhibited
malate-respiring mitochondria (Fig. 2D). These observations indicate
that malate does not support SLP.
Uncouplers have been shown to stimulate mitochondrial SLP in
ATP synthase-inhibited mitochondria (Rigoulet et al., 1985). As a
control, the effect of the uncoupler FCCP was examined on ATP syn-
thesis in α-KG-supported, oligomycin-treated brain mitochondria. In
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the presence of oligomycin, the addition of the uncoupler (50 nM
FCCP instead of MB) increased the rate of ATP synthesis from
47 ± 3 nmol/min/mg protein to 103 ± 13 nmol/min/mg protein in
α-KG- respiring mitochondria (data not shown).
Supporting the data, the effects of MB and various mitochondrial
inhibitors on the most important bioenergetic functions are summa-
rized in (Table 1).
3.3. Effects of MB on the oxygen consumption in brain mitochondria
supported by various substrates
Oxygen consumption experiments followed a protocol which is
identical, except for minor modifications, to that used for the ATP
production measurements described under Section 3.2. Mitochondria
were first energised with various respiratory substrates, then addition
of ADP initiated state 3 respiration and OXPHOS, while oligomycin
inhibited ATP synthase and MB stimulated electron transfer from
NADH or FADH2 to cytochrome c. Experiments using α-KG and suc-
cinate as respiratory substrates were terminated by addition of CAT,
an inhibitor of ANT.
In oligomycin-treated, α-KG-energised mitochondria (Fig. 3A,B)
MB stimulated the oxygen consumption in a dose-dependent manner.
When mitochondria were challenged with MB, 57, 129, and 167%
increases in oxygen consumption were observed using 300 nM MB,
1 μM MB, and 2 μM MB, respectively, after ATP production had al-
ready been inhibited by oligomycin. The addition of CAT in the pres-
ence of MB triggered a moderate decrease in oxygen consumption.
In succinate-energised mitochondria, 300 nM MB, 1 μM MB, and
2 μM MB led to 93, 108, and 210% increase, of the oxygen consump-
tion rate, respectively, in the presence of oligomycin (Fig. 3C). CAT
induced no alteration in oxygen consumption which also indicated the
absence of SLP.
In glutamate-energised mitochondria 1 μM MB stimulated oxygen
consumption by 100% from 24 ± 4 to 48 ± 3 nmol/min/mg protein
provided that OXPHOS was inhibited by oligomycin (Fig. 3D). CAT
lowered oxygen consumption from 48 ± 3 to 31 ± 3 nmol/min/mg pro-
tein in MB-treated mitochondria (data not shown).
As shown in Fig. 3D, 1 μM MB increased the rate of O2 consump-
tion from 40 ± 2 to 61 ± 2 nmol/min/mg protein (a 52% enhancement)
in malate-respiring mitochondria. CAT induced no significant alter-
ation in O2 consumption in the presence of MB (data not shown).
3.4. Effects of MB on the NAD(P)H level
The protocol for the NAD(P)H autofluorescence measurements
followed the same steps as those of the 3.4. section. The respiratory
substrate (α-KG) increased the mitochondrial NAD(P)H level (Fig.
4). The ADP-accelerated respiration was accompanied by a decreased
steady-state level of NAD(P)H. In the presence of oligomycin, which
augmented the mitochondrial NAD(P)H level, MB (1 μM) signifi-
cantly decreased the NAD(P)H autofluorescence in α-KG-respiring
brain mitochondria (Fig. 4, trace c). In ATP synthase-inhibited mito-
chondria energised with α-KG, CAT further attenuated the NAD(P)H
level in the presence of MB. In contrast, in the absence of MB the ad-
ministration of CAT had no influence on the NAD(P)H autofluores-
cence in respiration-impaired, α-KG-energised mitochondria (Fig. 4,
trace b). These experiments demonstrated the ability of MB to oxidize
intramitochondrial NAD(P)H.
3.5. Effects of MB on the mitochondrial membrane potential (Δψm)
The Δψm was measured semiquantitatively via safranin-O fluo-
rescence in isolated mitochondria respiring on α-KG, succinate or
glutamate (Fig. 5.). The experimental protocol of the Δψm measure-
ment was similar to that of the NAD(P)H-level measurement (Sec-
tion 3.4). In the presence of respiratory substrates, the inner mitochon-
drial membrane became hyperpolarised. ADP was given, which de-
creased the Δψm, because the entry of protons through the FoF1-AT-
Pase lowered the proton motive force (Nicholls and Ferguson, 2013).
Oligomycin increased the Δψm due to the accumulation of protons in
the intermembrane space. In α-KG-supported mitochondria MB had
no significant influence on the Δψm, whereas the subsequent addition
of CAT slightly depolarised the Δψm (Fig. 5A, trace c). Contrary to
that, addition of CAT did not influence the Δψm when MB was omit-
ted (Fig. 5A, trace b). The MB-dependent unusual effect of CAT is
explained in the Discussion. In succinate-energised mitochondria after
the ATP-synthase was inhibited by oligomycin, the effect of MB was
negligible (Fig. 5B, trace c). In contrast to that observed with α-KG,
the addition of CAT did not alter the Δψm in the presence of MB for
succinate-energised, OXPHOS-impaired mitochondria (Fig. 5B, trace
b). Moreover, in glutamate-respiring mitochondria, MB added after
oligomycin treatment also did not influence the Δψm (Fig. 5C, trace c)
but CAT led to depolarization in MB-treated mitochondria similarly
to that found in α-KG-supported mitochondria (Fig. 5C, trace c).
3.6. Effects of MB on mitochondrial bioenergetics in ATP-synthase-
and complex I- inhibited mitochondria
Complex I impairment is implicated in several neurodegenerative
diseases (for review see (Bose and Beal, 2016; Chaturvedi and Beal,
2013)). The aim of the experiments was to reveal whether the en-
hancing effect of MB on SLP could also be detected in complex I-in-
hibited mitochondria. Rotenone was used to inhibit Complex I, in all
Table 1
Effects of ADP, oligomycin, methylene blue (MB), and carboxyatractilozide (CAT), given in various combinations, on respiration, ATP synthesis, or membrane potential in alpha-ke-
toglutarate (α-KG) respiring mitochondria. In the first column the above compounds are listed in the order of their addition, (bold letters indicate the last added chemical) whereas the
respective gross effects of that compund are indicated in the subsequent columns. Abbreviations: SLP, substrate-level phosphorylation.
Compounds added to mitochondria Respiration ATP synthesis Membrane potential
α-ketoglutarate Basal respiration (state2) No ATP synthesis Hyperpolarisation
α-KG + ADP Stimulated respiration (state3) Maximal OXPHOS + SLP Slight depolarisation
α-KG + ADP
+oligomycin
Inhibition Inhibitied OXPHOS,
decreased SLP
Hyperpolarisation
α-KG + ADP + oligomycin + MB Increase Inhibited OXPHOS,
stimulated SLP
No change
α-KG + ADP + oligomycin + MB + CAT Decrease Inhibited OXPHOS
Inhibited SLP
Slight depolarisation
α-KG + ADP + CAT Decrease Decreased OXPHOS
Decreased SLP
Hyperpolarisation
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Fig. 3. The effect of MB on the rate of oxygen consumption in α-ketoglutarate (A;B) and succinate (C), glutamate (D) and malate (D) supported brain mitochondria. Representative
experiments with original traces are shown in (A). AP5 (200 μM) was added to each sample. Mitochondria (0.1 mg/ml) were incubated in the standard medium as described under
Materials and methods. ADP (2 mM), oligomycin (2 μM), MB (300 nM, 1 μM, 2 μM) and carboxyatractilozide (CAT; 2 μM) were given as indicated. The effect of MB (1 μM) (trace
c) is compared with controls (without oligomycin and MB: trace a; and without MB: trace b). The results are expressed as the mean oxygen consumption in nmol/min/mg protein ±
SEM (n > 4) and written on the bars; *p < 0.05; ***p < 0.001. The values n in the figures refer to the number of repetitions in each group.
of the experiments. In the following experiments, oligomycin and the
complex I inhibitor rotenone were applied in parallel.
3.6.1. Effects of MB on ATP synthesis
Addition of ADP and α-KG or malate initiated OXPHOS.
Oligomycin plus rotenone inhibited ATP-synthase and complex I
which inhibitions were accompanied by the decrease of ATP pro-
duction (Fig. 6A). Challenging the α-KG-treated mitochondria with
MB increased the rate of ATP synthesis by 59% (from 17 ± 2 to
27 ± 2 nmol/min/mg protein) in case of 1 μM MB and by 282% (from
17 ± 2 to 65 ± 10 nmol/min/mg protein) with 2 μM MB. However, in
malate-energised mitochondria MB when added after oligomycin plus
rotenone did not increase the rate of ATP generation (Fig. 6A).
3.6.2. Effects of MB on Δψm
In α-KG or malate-energised mitochondria, addition of the res-
piratory substrate hyperpolarised the mitochondrial membrane while
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Fig. 4. The effect of MB on the steady-state level of NAD(P)H in α-ketoglutarate-sup-
ported brain mitochondria. AP5 (200 μM) was added to each sample. Mitochondria
(0.1 mg/ml) were incubated in the standard medium as described under Materials and
methods. ADP (2 mM), oligomycin (2 μM), MB (1 μM) and carboxyatractilozide
(CAT; 2 μM) were given as indicated. The effect of MB (trace c) is compared with con-
trols (without oligomycin and MB: trace a; and without MB: trace b).
ADP caused depolarisation. Oligomycin augmented the Δψm, as was
seen previously (Fig. 5.), while rotenone decreased the Δψm inhibiting
the electron flow. 2 μM MB restored the Δψm both in α-KG- (Fig. 6A)
or malate-supported (Fig. 6B) mitochondria. At the end of each exper-
iment FCCP was added to dissipate the Δψm.
3.6.3. Effects of MB on the steady-state level of NAD(P)H
The protocol for the NAD(P)H autofluorescence measurements
was identical to the one of the 3.6.2 section. Mitochondria were in-
cubated in the presence of MB (Fig. 7A, trace a) or in the absence
(Fig. 7A, trace b) of MB. As described in Section 3.4, in the ab-
sence of MB (Fig. 7A, trace b) α-KG augmented the NAD(P)H fluo-
rescence, while ADP lowered the steady-state level of NAD(P)H and
oligomycin increased the NAD(P)H level. The subsequent addition of
FCCP oxidized the NAD(P)H pool. Administration of the complex I
inhibitor rotenone elevated the NAD(P)H level. On the contrary, the
MB (2 μM) which was present throughout the experiment (Fig. 7A,
trace a) modified the NAD(P)H steady-state of mitochondria. In the
presence of MB the changes in the NAD(P)H level were rather mod-
erate relative to the control indicating the ability of MB to oxidize
NAD(P)H.
3.6.4. Mitochondrial accumulation of MB in α-KG-respiring
mitochondria
Owing to the aromatic rings and the positive charge of MB, it is
able to cross the mitochondrial membranes and accumulate in the mi-
tochondrial matrix (Gabrielli et al., 2004). In order to verify the mi-
tochondrial uptake of MB, the oxidized MB's absorbance was mea-
sured at 660 nm in the presence of isolated brain mitochondria (Fig.
7B). MB (2 μM) was added to mitochondria at the beginning of each
experiment. This was followed by the addition of α-KG which re-
sulted in a drop in absorbance indicating the reduction (and uptake)
of MB. OXPHOS was initiated by ADP resulting in a subtle elevation
of level of oxidized MB. Administration of oligomycin caused mem-
brane hyperpolarisation (Fig. 5A.), elevation of the NAD(P)H level
(Fig. 4.) and an increase in the concentration of reduced MB. The un-
coupler FCCP, increased the absorbance of MB to its maximum level,
indicating the near complete oxidation of the dye. Challenging mito-
chondria with rotenone in the presence of FCCP resulted no change in
the absorbance of MB. The measurements were always terminated by
dithionite, which completely reduced MB.
4. Discussion
The aim of the present study was to examine the effects of MB
on mitochondrial SLP. The substrate specificity of the MB-stimulated
SLP was also investigated. Succinyl-CoA is a product of the α-ke-
toglutarate dehydrogenase (α-KGDH)-catalysed reaction in the TCA
cycle. Succinyl-CoA ligase provides ATP via SLP for mitochondria
even in the absence of oxygen (Weinberg et al., 2000) or when the
respiratory chain is impaired (Kiss et al., 2013). Maintaining a low
NADH/NAD+ ratio in the mitochondrial matrix is crucial for an ef-
fective SLP. A high NADH concentration inhibits the activity of the
α-KGDH (Smith et al., 1974) and hence the α-KGDH under this con-
dition cannot provide succinyl-CoA, a substrate for succinyl-CoA lig-
ase. In anoxia or respiratory chain impairment, diaphorases are capa-
ble of sustaining an adequate level of NAD+ for the α-KGDHc via the
oxidation of NADH (Chinopoulos et al., 2010; Kiss et al., 2013). Re-
duction in the α-KGDHc activity, which is often associated with neu-
rodegeneration (Gibson et al., 2000), which decreases the availabil-
ity of succinyl-CoA for matrix SLP (Kiss et al., 2013). Data from the
Chinopoulos group (Chinopoulos et al., 2010; Kiss et al., 2013) sug-
gest that the SLP might be able to provide a rescue mechanism for cell
survival via generating ATP independently from the respiratory chain
in mitochondria; this mechanism can also prevent the reversal of the
ANT and the mitochondrial consumption of cytosolic ATP.
To be able to selectively measure the SLP all possible ATP form-
ing reactions had to be considered. In our experiments, the contribu-
tion of adenylate kinases (AKs) to mitochondrial ATP production was
not negligible (Fig. 1.). To minimise this contribution, an inhibitor
of AKs, AP5 (200 μM) (Melnick et al., 1979) was used through-
out the experiments. Without AP5, the ATP synthesis attributed to
the AK isoenzymes decreased as a function of time (Fig. 1.), pre-
venting the accurate detection of SLP. To eliminate the contribution
of OXPHOS to ATP synthesis, the FoF1-ATPase was inhibited by
oligomycin throughout the experiments.
4.1. The mitochondrial “target” of MB
To be able to influence mitochondrial functions, MB has to en-
ter the mitochondria. MB is able to cross the mitochondrial mem-
branes in a Δψm-dependent manner and accumulate in the mitochon-
drial matrix (Gabrielli et al., 2004). In order to prove the mitochondr-
ial translocation of MB in our systems, the absorbance of the oxidized
MB was followed at 660 nm (Fig. 7B). In the presence of mitochon-
dria, but in the absence of respiratory substrates MB remained fully
oxidised (its absorbance was maximal). The addition of oligomycin
was found to be coupled to the increased level of reduced MB, while
this effect was eliminated by the addition of the uncoupler that re-
duced the uptake of MB via depolarisation of Δψm. A correlation
was found between the oxidation-reduction states of MB and that of
NAD(P)H (Fig. 7A,B); a higher NAD(P)H level appeared to be asso-
ciated with a higher level of reduced MB (measured as the reduction
of absorbance at 660 nm): this correlation was eliminated by the ad-
dition of the uncoupler (the Δψm collapsed, which prevented the ac
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Fig. 5. The effect of MB on safranin fluorescence indicating Δψm in α-ketoglutarate (A), succinate (B), and glutamate (C) supported brain mitochondria. AP5 (200 μM) was added to
each sample. Mitochondria (0.1 mg/ml) were incubated in the standard medium as described under Materials and methods. ADP (2 mM), oligomycin (2 μM), MB (1 μM), carboxy-
atractilozide (CAT; 2 μM) and FCCP (250 nM) were given as indicated. The effect of MB (trace c) is compared with controls (without oligomycin and MB: trace a; without MB:
trace b). Each trace represents an average ± SEM of three independent experiments.
cumulation of MB). Therefore, in the presence of the uncoupler
(FCCP) rotenone increased the NAD(P)H level but no reduction of
MB could be detected (Fig. 7A,B). These observations can be ex-
plained by the fact that low concentrations of MB (0.5–2 μM) were
capable of accepting electrons from NAD(P)H and FADH2 providing
an alternative pathway for transferring electrons onto cytochrome c
when the respiratory chain was impaired (Atamna et al., 2008; Wen et
al., 2011). This alternative electron transfer mechanism bypasses com-
plexes I and/or III, therefore changes the efficiency of proton pump-
ing: in case of NADH from 10 H+/NADH to 2H+/NADH, and with
succinate-FADH2 from 6 H
+/FADH2 to 2H
+/FADH2 (Tretter et al.,
2014). The decrease in pumping efficiency likely stimulates oxidation
with all of the respiratory substrates undergoing oxido-reduction.
In this study, various respiratory substrates were applied to ener-
gise isolated guinea pig brain mitochondria. The effects of MB on
mitochondrial SLP, oxygen consumption, Δψm and NAD(P)H auto-
fluorescence were investigated in α-KG-, succinate-, glutamate- or
malate-supported mitochondria. To support understanding a short
summary of the effects of the chemicals used in this study was pro-
vided in Table 1.
4.2. The effects of MB on mitochondria utilising α-KG
In α-KG-supported mitochondria in the presence of oligomycin,
the rate of ATP synthesis (47 ± 3 nmol/min/mg protein) was higher
than that observed in the absence of α-KG (23 ± 1 nmol/min/mg pro-
tein) and in the presence of 2 mM ADP (Fig. 2B). This elevation was
attributed to the basal α-KG-stimulated mitochondrial SLP. MB added
at various concentrations caused a dose-dependent increase of SLP.
MB-induced SLP was most efficient with α-KG as compared to other
respiratory substrates. In α-KG-supported and oligomycin-treated mi-
tochondria challenge with MB resulted in the decrease of NAD(P)H
autofluorescence. Subsequent addition of CAT further reduced the
NAD(P)H level in the MB-treated mitochondria (Fig. 4,
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Fig. 6. The effects of combined inhibition of the ATP-synthase and complex I on SLP and on Δψm of mitochondria supported by α-KG or malate. Effect of MB on ATP synthesis
(A) and on Δψm in α-ketoglutarate (B) and malate–respiring (C) mitochondria. AP5 (200 μM) was added to each sample. Mitochondria were incubated in the standard medium as
described under Materials and methods. ADP (2 mM), oligomycin (2 μM), rotenone (1 μM) and MB (1 μM, 2 μM) or FCCP (250 nM) were added as indicated. The results are ex-
pressed as rate of ATP synthesis in nmol/min/mg protein mean ± SEM (n > 4) and written on the bars; ***p < 0.001 (A). For (B) and (C) traces are representative of at least three
independent experiments. The values n in the figures refer to the number of repetitions in each group.
trace c). This phenomenon indicated that the inhibition of ANT kept
SLP-produced ATP inside the mitochondria; accumulation of ATP
could inhibit the α-KGDHc (Lawlis and Roche, 1981) and result in
decreased NADH + H+ levels. However, in the absence of MB the
NAD(P)H level did not diminish after giving CAT (Fig. 4, trace b).
This demonstrated that basal SLP likely did not produce enough ATP
to inhibit the α-KGDHc. This explanation was further supported by
our observations which demonstrated that in the absence of MB the
inhibition of the ANT did not significantly decrease respiration. How-
ever, in ATP-synthase-inhibited mitochondria respiring on α-KG MB
stimulated respiration and the inhibition of the ANT decreased the rate
of oxygen consumption (Fig. 3B). This phenomenon demonstrates the
inhibition of the α-KGDHc by SLP-mediated ATP.
Additionally, these observations appeared to be also supported
by the Δψm measurements. In the presence of MB CAT caused de-
polarisation, which could be explained by the above mentioned in-
hibitory effect of ATP on the α-KGDHc that results in a decrease in
NADH + H+ production (Fig. 5A, trace c). In the absence of MB, mi-
tochondria responded to ANT inhibition by slight hyperpolarisation
because the normal forward function of the ANT leads to a decreased
proton gradient (Fig. 5A, trace b) (Brand et al., 2005; Chinopoulos et
al., 2009; Klingenberg, 2008; Villiers et al., 1979).
4.3. The effects of MB on mitochondria utilising succinate
Mitochondria supported by succinate reacted differently to MB
treatment. The lack of stimulation of basal SLP in succinate-treated
mitochondria (Fig. 2C), which is different from that observed with
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Fig. 7. Interaction between NAD(P)H and MB in intact brain mitochondria. The effect of MB on the steady-state level of NAD(P)H in α-ketoglutarate-supported brain mitochondria
(A). AP5 (200 μM) was present in each sample. Mitochondria (0.1 mg/ml) were incubated in the standard medium as described under Materials and methods. α-KG (5 mM), ADP
(2 mM), oligomycin (2 μM), FCCP (1 μM), and rotenone (1 μM) were given as indicated. MB (2 μM) was present (trace a, black line) or absent (trace b, grey line) in the buffer.
Changes in the oxidation state of MB in α-KG-respiring mitochondria (B). Increase of absorbance at 660 nm indicates oxidation of MB and vice versa. Mitochondria were incubated
under the conditions of Fig. 7A, trace a. At 900 sec dithionite was added as indicated. For both (A) and (B) traces are representatives of at least three independent experiments.
α-KG, supported the results of a previous study (Kiss et al., 2013)
wherein succinate did not contribute to the mitochondrial SLP. Al-
though MB was able to increase the rate of oxygen consumption,
this stimulation was not associated with an increased ATP production.
Furthermore, CAT did not inhibit the MB-stimulated respiration indi-
cating that succinate oxidation was not associated with ATP produc-
tion under these conditions. In succinate-supported mitochondria MB
did not decrease significantly the NAD(P)H level, and CAT did not
decrease the steady-state level of NAD(P)H (data not shown). In mi-
tochondria treated with oligomycin and MB CAT did not depolarize
Δψm (Fig. 5B). These findings suggest that in the presence of succi-
nate and MB the SLP-mediated ATP production is not active.
4.4. The effects of MB on mitochondria utilising glutamate
In glutamate-energised mitochondria, basal level of SLP was de-
tected (31 ± 4)-(23 ± 1) = 8 ± 2 nmol/min/mg protein, while MB
could further stimulated SLP in the presence of oligomycin (Fig.
2D). The smaller rate of SLP observed in glutamate-supported mito-
chondria relative to α-KG-respiring mitochondria, is explained by the
two-step dehydrogenation of glutamate to succinyl-CoA via the suc-
cessive actions of glutamate dehydrogenase and the α-KGDHc: oxi-
dation of 1 mol NADH allows formation of 1 mol of succinyl-CoA
in α-KG-supported mitochondria. However, the oxidation of 1 mol of
NADH results in only 0.5 mol of succinyl-CoA in the oxidative catab-
olism of glutamate. The decreased yield of succinyl-CoA formation
was reflected in the reduced rate of the SLP in glutamate-supported
mitochondria (Fig. 2D). Measurements for Δψm and oxygen consump-
tion carried out in the presence of glutamate showed similarities to
those performed in the presence of α-KG. We concluded that regard-
ing the SLP there is only a quantitative difference exists between glu-
tamate and α-KG-energised mitochondria.
4.5. The effects of MB on mitochondria utilising malate
Mitochondria energised by malate did not support SLP in either
the absence or presence of MB. Considering the role of malate in the
TCA cycle the probability of malate contributing to the formation of
succinyl-CoA and to SLP is low (Kiss et al., 2013). Similarly to other
respiratory substrates investigated in this study, in malate-oxidising
mitochondria, MB (1 μM) was able to stimulate oxygen consumption
in the presence of oligomycin (Fig. 3D). However, this stimulation of
respiration did not result in an enhanced ATP production (Fig. 2D).
4.6. Relationship between oxygen consumption, MB, and ATP
production in oligomycin-treated mitochondria
As described above, the contributions of the different respiratory
substrates to the SLP-mediated ATP production are dissimilar. Con-
sidering the unequal oxidation rates of the respiratory substrates, the
efficiency of the SLP-mediated ATP production in relation to oxygen
consumption should be further examined. We calculated a parame-
ter whose bioenergetic interpretation is similar to the one of P/O ra-
tio; the P/O ratio is frequently used in mitochondrial physiology, and
quantifies the efficacy of ATP production in relation to oxygen con-
sumption (Chance and Williams, 1956; Lee et al., 1996; Lehninger
and Smith, 1949). Taking into account that the P/O ratio (ATP produc-
tion/O2 consumption) calculations use nanogram atoms of oxygen in-
stead of nanomoles (Lee et al., 1996), the ΔP/ΔO ratio after treatment
with 2 μM MB was (96–47)/(2*(56–21) = 0.7 for α-KG and (24–19)/
2*(124–40) = 0.03 for succinate. This was calculated from the differ-
ence of the rate of ATP generation detected after MB treatment and
the basal SLP and divided by the difference of the rate of O2 con-
sumption detected after MB administration and oligomycin addition:
the maximum P/O ratio in the absence of OXPHOS is one. The dif-
ference between the theoretical maximum 1 and the calculated ratio
0.7 can be explained by the less than 100% efficacy of ATP detection,
the possibility that mitochondria may use a certain portion of the pro-
duced ATP themselves, and the increased formation of reactive oxy-
gen species in MB-treated mitochondria (Tretter et al., 2014).
To illustrate the effects of MB on oxygen consumption and on ATP
production, data taken from Figs. 2 and 3 were compared in Fig. 8:
the dependence of ATP production on oxygen consumption was plot-
ted. Our findings demonstrate that from the respiratory substrates in-
vestigated in this study only α-KG and glutamate reacted with an in-
creased rate of ATP synthesis to MB-stimulated oxidation. Contrary
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Fig. 8. Relationship between the rate of ATP production and oxygen consumption in
the presence or absence of MB in oligomycin-treated mitochondria supported by var-
ious respiratory substrates: α-ketoglutarate (black circles, solid line), succinate (black
triangles, solid line), glutamate (white circles, long dash) and malate (white triangles,
dotted) energised mitochondria. Mitochondria were incubated in the standard medium
as described under Materials and methods. ADP (2 mM), oligomycin (2 μM) and MB
(0–2 μM) were given. MB concentrations (μM) are indicated in brackets. Data were
taken from Fig. 2 and 3., respectively. The results are expressed as the mean oxygen
consumption and as the mean ATP production in nmol/min/mg protein ± SEM (n > 4).
to that MB similarly stimulated oxygen consumption but hardly in-
creased ATP production in succinate and malate-energised mitochon-
dria (Fig. 8).
4.7. The beneficial effects of MB in combined inhibition of
respiratory complex I and F1Fo ATP synthase
MB seems to be a neuroprotective agent in neurodegenerative
disease models (Atamna et al., 2012; Poteet et al., 2012). In neu-
rodegenerative diseases mitochondrial functions are usually impaired
(Chaturvedi and Beal, 2013). The most important mitochondrial func-
tions associated with bioenergetics are the synthesis of ATP and con-
tribution to the maintenance of ionic homeostasis of the cells. Inhi-
bition of respiratory complex I prevents the building up of Δψm and
the OXPHOS (Nicholls and Ferguson, 2013). These two mitochondr-
ial functions mutually dependent upon each other. Without Δψm there
is no OXPHOS and the reversal of ATP synthase function, ATP hy-
drolysis and proton pumping can be associated with Δψm formation
(Chinopoulos and Adam-Vizi, 2010). In mitochondria with the respi-
ratory complex I and ATP synthase inhibited MB partially restored
ATP synthesis and Δψm.
Herein we demonstrate that MB increases the SLP-coupled ATP
production in complex I-inhibited isolated brain mitochondria. This
phenomenon can contribute to the neuroprotective effects of MB in
neurodegenerative diseases. In oligomycin plus rotenone-treated
α-KG-respiring mitochondria MB greatly stimulated ATP production
(Fig. 6.). However, in malate-energised mitochondria MB did not in-
crease the rate of ATP synthesis, which refers to the substrate-de-
pendency of the mitochondrial SLP. The effects of different mito-
chondrial substrates on SLP in the presence of MB are summarized
(Fig. 9). Contrary to the substrate-specific stimulation of the SLP, the
oligomycin plus rotenone induced collapse of Δψm was repolarized
Fig. 9. Summary of MB-stimulated changes in oxidative phosphorylation inhibited
brain mitochondria. Mitochondria supported by Complex I (CI) (glutamate or alpha-ke-
toglutarate or malate) or Complex II (CII) succinate substrate, respectively. MB ac-
cepts electrons from NADH and donates them to cytochrome c, thus the efficacy of
proton pumping is decreased. The decreased level of mitochondrial NADH (or FADH2
with succinate substrate) stimulates the activity of dehydrogenases and increases the
flux of the citrate cycle. Those substrates that can form succinyl-CoA (α-KG and glu-
tamate) will contribute to SLP, while succinate and malate are localized “downstream”
from the succinyl-CoA hence do not contribute to succinyl-CoA formation for SLP. Ab-
breviations: CI, CII, CIII, CIV: respiratory chain complexes, CV: mitochondrial F0F1
ATP-ase, GDH: glutamate dehydrogenase, α-KGDHc: alpha-ketoglutarate dehydroge-
nase complex, SDH: succinate dehydrogenase.
by MB even with that substrate (malate) which did not support SLP
(Fig. 6C). Taking into account that the directionality of the ATP and
ADP transport by the ANT is both concentration- and Δψm-dependent
(for a mathematical model see (Chinopoulos, 2011a; Metelkin et al.,
2009)) the repolarising effect of MB might prevent the hydrolysis of
cytosolic ATP by stimulating the oxidation of those substrates which
do not support SLP.
5. Conclusion
The ability of MB to accept and transfer electrons within the mito-
chondrial electron transport system combined with the positive charge
and lipophilic character of the compound make the Δψm-dependent
mitochondrial enrichment of MB possible. MB stimulates the oxida-
tion of NADH, hence it can also increase/restore the metabolic flux
inside the citric acid cycle, which is a prerequisite of SLP. Here we
conclude that the enhancement of SLP and the restitution of Δψm may
have beneficial effects under pathological conditions and could con-
tribute to the possible neuroprotective effects of MB.
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